DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Not Applicable

Completed

Conditions: Liver Cirrhosis

Interventions: Drug: Caffeine
Drug: Warfarin sodium
Drug: Omeprazole
Drug: Metoprolol
Drug: Midazolam

First Posted Date: 2023-02-23

Last Posted Date: 2025-01-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4

Registration Number: NCT05741385

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Not Applicable

Completed

Conditions: Liver Cirrhosis

Interventions: Drug: Rosuvastatin
Drug: Digoxin
Drug: Metformin hydrochlorid
Drug: Furosemide

First Posted Date: 2023-02-23

Last Posted Date: 2025-01-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT05741372

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo matching BI 1839100
Drug: BI 1839100
Drug: midazolam
Drug: digoxin
Drug: rosuvastatin

First Posted Date: 2023-02-22

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 67

Registration Number: NCT05738291

Locations: 🇳🇱
ICON-Groningen-62040, Groningen, Netherlands

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: BI 425809 (iclepertin)

First Posted Date: 2023-02-16

Last Posted Date: 2023-12-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT05731895

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems

Phase 1

Completed

Conditions: Healthy
Liver Diseases

Interventions: Drug: BI 690517

First Posted Date: 2023-02-16

Last Posted Date: 2023-05-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT05731908

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Omega Research Orlando, LLC, Orlando, Florida, United States

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: BI 765250
Drug: Placebo

First Posted Date: 2023-02-15

Last Posted Date: 2025-03-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT05728489

Locations: 🇧🇬
MBAL Sveta Sofia, Sofia, Bulgaria
🇬🇪
ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia
🇲🇩
Clinical Republican Hospital "Timofei Mosneaga", Chisinau, Moldova, Republic of

and more 2 locations

A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809
Drug: bosentan

First Posted Date: 2023-02-13

Last Posted Date: 2023-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT05723874

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems

Phase 1

Completed

Conditions: Renal Insufficiency
Healthy

Interventions: Drug: BI 1015550

First Posted Date: 2023-02-08

Last Posted Date: 2023-09-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 26

Registration Number: NCT05718648

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: BI 425809

First Posted Date: 2023-02-08

Last Posted Date: 2023-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT05718843

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer

Not Applicable

Recruiting

Conditions: Non-Small-Cell Lung Carcinoma
Pancreatic Ductal Adenocarcinoma
Colorectal Cancer

Interventions: Diagnostic Test: Liquid biopsy

First Posted Date: 2023-02-01

Last Posted Date: 2024-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 180

Registration Number: NCT05708599

Locations: 🇩🇪
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy